Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DepleTTR-CM: ALXN2220 in Transthyretin Amyloid Cardiomyopathy
jRCT2031230517Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in amyloidotic transthyretin cardiomyopathy (ATTR-CM) comparing ALXN2220 with Placebo (2 arms). Primary endpoint: Composite of all-cause mortality and total cardiovascular clinical events. Started Jan 2024; status: active, not recruiting.
02
Drugs
cliramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on jRCT2031230517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230517.